Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer response to lice study

This article was originally published in The Tan Sheet

Executive Summary

Conclusions on efficacy of Rid pediculicide cannot be drawn from recent in vitro study because University of Miami researchers "completely ignored" directions for use, Bayer says. Study in February Archives of Dermatology reported on kill rates of head lice exposed to cotton disks impregnated with OTC, Rx pediculicides (1"The Tan Sheet" March 4, 2002, p. 10). "Contrary to the method used in the study, Rid must be applied twice in a 10-day period, followed by combing on each occasion," Bayer says. "During each application lice are completely covered with Rid. The technique of placing lice on filter paper soaked with Rid, used in this study, would not be effective"...

You may also be interested in...



Pediculicide Formulation, Vehicle Differences Cited In Efficacy Study

The "large difference of efficacy" between two OTC pyrethrin products in a recent study is due to formulation and vehicle disparities in the lice remedies, researchers say in the February Archives of Dermatology

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel